Clinical trial
A Multi-ARM Phase Ib Study of SAR650984 (Isatuximab, an Anti-CD38 mAb) in Combination With Standard Carfilzomib, and High-dose Weekly Carfilzomib and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
NCT02332850 is registered in ClinicalTrials.gov with Thomas Martin, MD as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-ARM Phase Ib Study of SAR650984 (Isatuximab, an Anti-CD38 mAb) in Combination With Standard Carfilzomib, and High-dose Weekly Carfilzomib and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
- Lead sponsor
- Thomas Martin, MD
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- January 21, 2015
- Completion date
- December 31, 2025
- Enrollment
- 83 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.